DOI: https://doi.org/10.21203/rs.3.rs-961648/v1
Background
The role of tumor deposits (TDs) in TNM staging of colorectal cancer is controversial, especially the relationship with distant metastasis.
Purpose
The aim of this study was to determine the effect of TDs on the survival of colorectal cancer and the occurrence of distant metastasis, and to determine whether TDs (+) patients behaved similarly to stage IV patients.
Methods
Retrospective analysis of CRC patients from two large independent cohorts from the Surveillance Epidemiology and End Results (SEER) database (n=58775) and the First Affiliated Hospital of Dalian Medical University (n=742).
Results
Univariate logistic analyses revealed that TDs as an independent predictor of liver metastasis [p<0.001; odds ratio (OR): 5.738; 95% confidence interval (CI): 3.560-9.248] in the The First Affiliated Hospital of Dalian Medical University’s patients. Meanwhile, TDs was also an independent predictor of isolated organ metastasis [p<0.001; odds ratio (OR): 3.028; 95% confidence interval (CI): 2.414 - 3.79; multiple organ metastases [p<0.001; odds ratio (OR): 4.778; 95% confidence interval (CI): 4.109 - 5.556]; isolated liver metastasis [p<0.001; odds ratio (OR): 4.395; 95% confidence interval (CI): 4.099 - 4.713] and isolated lung metastasis [p<0.001; odds ratio (OR): 5.738; 95% confidence interval (CI): 3.560-9.248] in the SEER database. Multivariate analyses suggested TDs were an independent poor prognostic factor for distant metastasis (p<0.001).
Conclusions
Our results have shown that compared with patients with negative TDs, CRC patients with positive TDs are more likely to develop distant metastasis. Patients who categorized T4aN2bM0 TDs (+) and T4bN2M0 TDs (+) have similar prognosis as those with stage IV, and these patients should be classified as stage IV.
It is estimated that by 2020, there will be 140,000 new cases of colorectal cancer and 50,000 deaths in the United States, ranking fourth and second in morbidity and mortality respectively(1). In China, the latest cancer statistics reported by the National Cancer Center in 2019 show that the incidence of colorectal cancer in our country is ranked third, the mortality rate is ranked fifth, and the mortality rate is generally on the rise(2). In recently years, great progress has been made in the early diagnosis and treatment of colorectal cancer, but the 5-year survival rate of colorectal cancer is still unsatisfactory, mainly because most of patients were diagnosed as terminal or distant metastasis(3). The prognosis of colorectal cancer depends on different clinical and pathological factors, many of which have been incorporated into different staging systems(4). Tumor staging is the basis of cancer therapy, and the TNM staging system, based on histopathological and radiological classification methods, is currently considered as the gold standard for various tumor staging(5). After the diagnosis of colorectal cancer, detailed staging can enable patients to benefit from more precise treatment methods.
Tumor deposits (TDs) are tumor cells clustered around colorectal cancer and mesenteric adipose tissue. The microscopic features of TDs are discrete foci far away from the front of aggressive tumors, and there are no signs of residual lymph nodes(6). TDs are significantly correlated with poor prognosis after colorectal cancer surgery(7, 8).Whether to consider TDs as positive lymph nodes in determining the TNM staging of colorectal cancer has been widely debated for many years, which has led to modifications and changes in subsequent versions of the TNM staging system. Both AJCC 7th TNM and AJCC 8th TNM classified regional LNM-negative, TDs-positive pT lesions as N1c(9). The existence and quantity of TDs are strongly correlated with the prognosis of colorectal cancer patients(6, 10–12), and more and more people support that the TDs as a sign of distant metastasis.
Part of colorectal cancer patients enrolled in the Surveillance, Epidemiology, and End Results (SEER) database and The First Affiliated Hospital of Dalian Medical University were included in this study to explore the impact of TDs on the survival and prognosis of patients and the relationship between TDs and distant metastasis.
The treatment data of stage I-IV CRC patients in the two groups were analyzed retrospectively. The first set of data comes from the SEER database, with a total of 970,163 patients with colorectal cancer. Inclusion and exclusion criteria: (1) Tumor site was restricted to the colon and rectum according to the international Classification of Diseases Code version 3 (ICD-O-3/WHO2008); (2) Select the treatment method for primary tumor resection, the operation code is limited to 30, 32, 40, 41, 50, 51, 60, 61, 70, and 80 to screen patients after surgery. (3) Include diagnostic age, gender, race, AJCC staging, TNM staging, primary site, tumor grade, TDs, neurological invasion, liver metastasis, lung metastasis, bone metastasis, brain metastasis, survival time, survival status, etc. A total of 80428 patients were obtained; (4) Patients with incomplete information above were excluded. In the end, a total of 58,775 patients who met the screening criteria were included (Figure 1).
The second set of data comes from the Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, and selected 742 CRC patients who underwent surgical treatment from January 2011 to December 2015. Inclusion and exclusion criteria: (1) Patients undergoing surgery for colorectal cancer for the first time; (2) Postoperative pathologically confirmed colorectal cancer; (3) No radiotherapy or chemotherapy was performed before surgery; (4) Postoperative tumor progression originated from Colorectal cancer; (5) Exclude a history of colorectal cancer surgery; (6) Exclude other malignant tumors; (7) Exclude patients undergoing radiotherapy and chemotherapy before surgery.
All statistical analyses were performed using SPSS 26.0. The Chi-square test was used to analyze the demographic and clinical characteristics of categorical variables. The logistical regression coefficients were used to estimate the odds ratios (OR) for the relationship between TDs and distant metastasis patterns. The Kaplan-Meier curve was used to calculate the survival rate, and the log-rank test was used to assess the difference. Calculated hazard ratio (HR) and 95.0% confidence interval (CI). Cox proportional hazards model was used for univariate and multivariate analysis. In multivariate analyses, the clinicopathological characteristics with p<0.05 in univariate analysis were included to determine independent prognostic factors. Significance was set at p < 0.05.
We extracted two sets of data, including 58,775 and 742 CRC patients, respectively. Overall, the TDs positive patients in SEER database and the First Affiliated Hospital of Dalian Medical University were 12.07% (n = 7096) and 27.90% (n = 207), respectively.
In the SEER database, the most common sites of metastasis are the liver (8.29%, n=4874), followed by the lung (1.74%, n=1024), bone (0.27%, n=159), and brain (0.09%, n=54). Only liver metastasis (11.46%, n=85) was shown in the data from the The First Affiliated Hospital of Dalian Medical University. Table 1 shows detailed clinicopathological data from the SEER Database and the The First Affiliated Hospital of Dalian Medical University.
Compared to the patients with negative TDs, the patients with positive TDs was significantly associated with worse OS in the entire cohort (54.37 vs 36.56 months, p<0.001) and stage IV cohort (29.36 vs 22.21 months, p<0.001). In order to better investigate the significance of TDs in stage IV patients, we divided the stage IV patients into isolated organ metastasis cohort and multiple organ metastases cohort, and the isolated organ metastasis group was further divided into isolated liver metastasis group and isolated lung metastasis group. The results showed that TDs positive patients still showed worse OS in the isolated organ metastasis cohort (30.59 vs 22.55 months, p<0.001) and multiple organ metastases cohort (18.92 vs 16.18 months, p=0.027). Similarly, the same results were obtained in the isolate liver metastasis cohort (30.59 vs 22.55 months, p<0.001) and isolate lung metastasis cohort (30.59 vs 22.55 months, p<0.001, Figure. 2).
Univariate analysis in the entire cohort demonstrated that age, gender, race, AJCC staging, TNM staging, primary site, tumor grade, TDs, neurological invasion, liver metastasis, lung metastasis, bone metastasis, brain metastasis affects the patient's OS. Moreover, multivariate analyses demonstrated that TDs was an independent prognostic factor. Using TDs negative as a reference, patients with positive TDs represented worse OS (HR=1.346, 95%CI: 1.296-1.398, p<0.001, Table 2).
3.4. TDs was an independent risk factor for distant metastasis in SEER and the The First Affiliated Hospital of Dalian Medical University cohort
In order to study the relationship between TDs and distant metastasis, we compared the positive rates of TDs in various metastasis patterns. The results showed that the positive rates of TDs in distant metastasis cohort, isolated organ metastasis cohort, multiple organ metastases cohort, isolated liver metastasis cohort and isolated lung metastasis cohort were 37.28%, 33.65%, 38.85%, 33.81%, 29.16%, respectively. This was significantly higher than the TDs positive rate in the SEER cohort. Moreover, the chi-square test showed that the distribution of TDs in the above cohorts was statistically significant (p<0.001, Figure. 3).
We further performed univariate and multivariate logistic regression analyses on variables in the two large cohorts to investigate the risk factors affecting patients with distant metastasis. Univariate logistic analyses revealed that TDs was an independent predictor of liver metastasis [p<0.001; odds ratio (OR): 5.738; 95% confidence interval (CI): 3.560-9.248] in the The First Affiliated Hospital of Dalian Medical University’s patients. Meanwhile, TDs was also an independent predictor of isolated organ metastasis [p<0.001; odds ratio (OR): 3.028; 95% confidence interval (CI): 2.414 - 3.797]; multiple organ metastases [p<0.001; odds ratio (OR): 4.778; 95% confidence interval (CI): 4.109-5.556]; isolated liver metastasis [p<0.001; odds ratio (OR): 4.395; 95% confidence interval (CI): 4.099-4.713] and isolated lung metastasis [p<0.001; odds ratio (OR): 5.738; 95% confidence interval (CI): 3.560-9.248] and in the SEER database. Multivariate analyses suggested TDs were an independent adverse prognostic factor for distant metastasis (p<0.001, Table 3).
We wondered whether some stage III TDs positive patients were already showing similar outcomes to stage IV patients? We performed a survival analysis for each subcategory of stage III and stage IV patients, survival information are shown in Table 4 and Figure 4, where T3aN2bM0 TDs (+) and T4N2M0 TDs (+) patients showed the average survival period similar to patients in stage IV (28.8, 24.8 and 29.3 months, respectively) and different to those in stage IIIc (41.5 months), stage IIIb (52.7 months), and stage IIIa (60.3 months) (p < 0.001).
Gabriel et al. first reported TDs in rectal cancer patients in 1935, believing that it was a blood derived metastasis confined to the surrounding tumor rather than a lymph node metastasis(13). Goldstein et al. conducted postoperative pathology biopsies of 418 patients with T3N+M0 colorectal cancer. They found that TDs were usually distributed in large blood vessels, perinerves or blood vessels near the primary tumor and formed when the tumor extended beyond the proper muscle. They are different from lymph node metastasis and should be described separately from lymph node metastasis(10) .This may help explain the correlation between TDs and patients' short survival time and their susceptibility to intraperitoneal metastasis. Yamano et al. divided TDs into infiltrating TDs (iTDs: cancer cell aggregates with lymphatic or perineural infiltration or cancer cell clusters) and nodular TDs (nTDs: smooth or irregularly shaped cancer cells without iTDs), found that iTDs and nTDs are independent poor prognostic factors for recurrence-free survival in patients with lymph node metastasis, and colorectal cancer patients with positive iTDs often have liver metastasis, and the probability of transition to distant lymph nodes is higher than that of patients with positive nTDs. This finding suggests that in patients with colorectal cancer, tumor cells in iTDs may transfer to the liver through the portal vein system and then to lymph nodes far away from the liver (14).
This study aims to clarify the effect of TDs on the prognosis of colorectal cancer patients, including the occurrence of distant metastasis and death. We found that for overall patients, TDs-positive patients had poor OS, which was similar to the results reported in the previous study (6, 7, 11, 15). We also found that the TDs are still affect patients with distant metastasis independent prognostic factors for survival. However, the latest version of TNM staging only considers TDs without lymph node metastasis, which may lose useful information. For patients with both lymph node metastasis and TDs positive, it is not clear whether TDs has an adverse effect on prognosis and whether it should be included in TNM staging. In addition, there is growing support for the inclusion of TDs in category M rather than N or T in TNM staging (16–18). The current version of the TNM staging does not mention the sites of TDs, but Yagi et al. emphasized the clinical significance of TDs in the tubercle area of pelvis. According to the metastatic status of the LPLN area, they divided 172 patients with stage Ⅱ and Ⅲ rectal cancer into three groups: patients without lymph node metastasis (no-LP-M group), patients with lymph node metastasis (LP-LNM group), and patients with TDs but without lymph node metastasis (LP-EX group). Multivariate Cox regression analysis showed that LP-EX is an important prognostic factor affecting OS and RFS, and the initial distant recurrence rate of LP-EX group (9/14, 64.3%) was significantly higher than other groups (42/158, 26.6 %) (P=0.006), indicating that TDs in extrapelvic lymph node area may be a systemic disease rather than a local disease (19). Tong et al. found that the prognosis of TDs-positive and negative colorectal cancer patients with T3N1cM0 stage was significantly different (P=0.038), and it was assumed that TDs in more than 7 lymph node metastases at the same time might be similar to cases with distant metastasis. The prognosis of these cases should be attributed to stage IV(18). Leonardo et al. conducted a cross-sectional study on 392 patients with colon adenocarcinoma, and grouped patients with stage I-III with TDs as “stage IV-TD”. According to statistical analysis, the average survival time of this patients was similar to that of patients in stage IV (69.3 months vs 64.6 months), but was different from that of patients in other stages (P<0.001). It can be seen that the current staging method does not fully consider the difference in the prognostic impact of TDs(20).
Although this study did not prove that TDs are directly related to stage IV patients, it is concluded that TDs are a risk factor for distant metastasis in CRC patients. Based on the above research, we should reconsider the meaning of TDs. In the long term, TDs have a good guiding significance for follow-up treatment. XiaoLi et al. found that TDs positive stage III CRC patients had a poor prognosis, and did not show that DFS benefited from chemotherapy. Therefore, for TDs positive patients, more detailed surgery and more rigorous follow-up are needed, as well as further research on optimal treatment strategies(21). At present, TDs are identified by pathological slices after surgery. Due to the lack of strict pathological examinations, and the recovery rate of lymph nodes varies with the quality of the operation, the detection of TDs has great heterogeneity. Although the latest advances in imaging have allowed MRI to detect TDs, it still takes a long time before it can be used in clinical practice(22). The circulating tumor cells (CTC), called "liquid biopsy", have always attracted much attention from scholars. CTC refers to the heterogeneous tumor cells that are released into the peripheral blood circulation from the primary tumor or metastasis due to spontaneous or diagnosis and treatment operations, and can be detected in the patient's peripheral blood(23). As mentioned above, TDs are closely related to distant metastases, but after surgical resection, they lose meaning in subsequent treatment and monitoring. As a more sensitive predictor, CTC has great practical significance for monitoring tumor recurrence and metastasis and treatment response(24). Therefore, we can focus on patients with positive TDs after surgery, and guide the follow-up treatment of patients by detecting the count and change trend of CTC in the blood, and monitor whether the patient has recurrence and metastasis. This kind of dynamic monitoring based on molecular characteristics can promptly select CRC patients who are at risk of metastasis, reduce unnecessary costs for patients and avoid the toxic side effects of related drugs, and guide patients to precise treatment is an inevitable trend in future development.
This study included the SEER database and the information of colorectal cancer patients in the The First Affiliated Hospital of Dalian Medical University, but there are still limitations. The data of the The First Affiliated Hospital of Dalian Medical University only contains information on liver metastasis. Information such as surgical procedures for tumors, some tumor markers, specific chemotherapy conditions, and the treatment of metastases may lead to deviations in research results.
In conclusion, colorectal cancer patients with negative TDs have better survival benefits than patients with positive TDs. And colorectal cancer patients with positive TDs are more likely to develop distant metastasis than patients with negative TDs. Therefore, large-scale, multi-center clinical studies should be carried out to prove the relationship between TDs and metastatic colorectal cancer, and the significance of TDs in colorectal cancer should be reconsidered.
CRC: Colorectal cancer
TDs: Tumor deposits
SEER: Surveillance, Epidemiology, and End Results
AJCC: American Joint Committee on Cancer
OS: Overall survival
LNM: Lymph node metastasis
iTDs: Cancer cell aggregates with lymphatic or perineural infiltration or cancer cell clusters
nTDs: Smooth or irregularly shaped cancer cells without iTDs
CTC: Circulating tumor cells
Availability of data and materials
Access to the database may be obtained from the corresponding author on reasonable request.
Data Statement
Our data are available and publicly accessible. The original data comes from the Surveillance, Epidemiology, and End Results (SEER) database and the Department of General Surgery, The First Affiliated Hospital of Dalian Medical University.
Acknowledgements
Not applicable
Funding
The study was supported by National Natural Science Foundation of China (Grant number: 81973646).
Author information
Affiliations
Department of General Surgery & Carson International Cancer Research Center, Shenzhen University General Hospital and Shenzhen University Clinical Medical Academy, Guangdong, Shenzhen, China
Wenhao Wu, Shun Zeng, Xianbin Zhang, Peng Liu & Peng Gong
Shenzhen University Clinical Medical Academy, Guangdong, Shenzhen, China
Tong Qiu & Shulin Li
Contributions
Peng Gong, Peng Liu designed the study; Tong Qiu and Shun Zeng collected the data; Wenhao Wu and Shulin Li analyzed the data and presented the results; Wenhao Wu and Xianbin Zhang wrote the manuscript. All of the authors listed have revised and approved the manuscript.
Corresponding author
Correspondence to Peng Gong
Ethics declarations
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University. The study outcomes will not affect the future management of the patients.
Consent for publication
The requirement for informed consent was waived.
Competing interests
The authors declare no conflicts of interest.
1. Siegel R, Miller K, Goding Sauer A, Fedewa S, Butterly L, Anderson J, et al. Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70(3):145-64.
2. Zhang SW SK, Zheng RS, Zeng HM, Wang SM, Chen R, Wei WQ, He J. Cancer incidence and mortality in China, 2015. JNCC. 2020.
3. Ye DX, Wang SS, Huang Y, Chi P. A 3-circular RNA signature as a noninvasive biomarker for diagnosis of colorectal cancer. Cancer Cell Int. 2019;19:276.
4. McClelland D, Murray G. A Comprehensive Study of Extramural Venous Invasion in Colorectal Cancer. PloS one. 2015;10(12):e0144987.
5. Tian Y, Xu T, Huang J, Zhang L, Xu S, Xiong B, et al. Tissue Metabonomic Phenotyping for Diagnosis and Prognosis of Human Colorectal Cancer. Scientific reports. 2016;6:20790.
6. Jin M, Roth R, Rock J, Washington M, Lehman A, Frankel W. The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. The American journal of surgical pathology. 2015;39(1):109-15.
7. Ueno H, Mochizuki H, Shirouzu K, Kusumi T, Yamada K, Ikegami M, et al. Actual status of distribution and prognostic impact of extramural discontinuous cancer spread in colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(18):2550-6.
8. Ueno H, Hashiguchi Y, Shimazaki H, Shinto E, Kajiwara Y, Nakanishi K, et al. Peritumoral deposits as an adverse prognostic indicator of colorectal cancer. American journal of surgery. 2014;207(1):70-7.
9. Liu F, Zhao J, Li C, Wu Y, Song W, Guo T, et al. The unique prognostic characteristics of tumor deposits in colorectal cancer patients. Annals of translational medicine. 2019;7(23):769.
10. Goldstein N, Turner J. Pericolonic tumor deposits in patients with T3N+MO colon adenocarcinomas: markers of reduced disease free survival and intra-abdominal metastases and their implications for TNM classification. Cancer. 2000;88(10):2228-38.
11. Nagtegaal I, Tot T, Jayne D, McShane P, Nihlberg A, Marshall H, et al. Lymph nodes, tumor deposits, and TNM: are we getting better? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(18):2487-92.
12. Pei JP, Zhang CD, Liang Y, Zhang C, Wu KZ, Li YZ, et al. A Modified Pathological N Stage Including Status of Tumor Deposits in Colorectal Cancer With Nodal Metastasis. Front Oncol. 2020;10:548692.
13. Gabriel WB, Dukes, C.,Bussey, H. J. R. Lymphatic spread in cancer of the rectum. British Journal of Surgery. 1935;23:395–413.
14. Yamano T, Semba S, Noda M, Yoshimura M, Kobayashi M, Hamanaka M, et al. Prognostic significance of classified extramural tumor deposits and extracapsular lymph node invasion in T3-4 colorectal cancer: a retrospective single-center study. BMC cancer. 2015;15:859.
15. Wong-Chong N, Motl J, Hwang G, Nassif G, Albert M, Monson J, et al. Impact of Tumor Deposits on Oncologic Outcomes in Stage III Colon Cancer. Diseases of the colon and rectum. 2018;61(9):1043-52.
16. Shimada Y, Takii Y. Clinical impact of mesorectal extranodal cancer tissue in rectal cancer: detailed pathological assessment using whole-mount sections. Diseases of the colon and rectum. 2010;53(5):771-8.
17. Lord A, D'Souza N, Pucher P, Moran B, Abulafi A, Wotherspoon A, et al. Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990). 2017;82:92-102.
18. Tong L, Gao P, Wang Z, Song Y, Xu Y, Sun Z, et al. Is the seventh edition of the UICC/AJCC TNM staging system reasonable for patients with tumor deposits in colorectal cancer? Annals of surgery. 2012;255(2):208-13.
19. Yagi R, Shimada Y, Kameyama H, Tajima Y, Okamura T, Sakata J, et al. Clinical Significance of Extramural Tumor Deposits in the Lateral Pelvic Lymph Node Area in Low Rectal Cancer: A Retrospective Study at Two Institutions. Annals of surgical oncology. 2016;23:552-8.
20. Lino-Silva L, Anchondo-Núñez P, Chit-Huerta A, Aguilar-Romero E, Morales-Soto J, Salazar-García J, et al. Stage I-III colon cancer patients with tumor deposits behave similarly to stage IV patients. Cross-section analysis of 392 patients. Journal of surgical oncology. 2019;120(2):300-7.
21. Li X, An B, Zhao Q, Qi J, Wang W, Zhang D, et al. Impact of tumor deposits on the prognosis and chemotherapy efficacy in stage III colorectal cancer patients with different lymph node status: A retrospective cohort study in China. International journal of surgery (London, England). 2018;56:188-94.
22. Lord A, Graham Martínez C, D'Souza N, Pucher P, Brown G, Nagtegaal I. The significance of tumour deposits in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990). 2019;122:1-8.
23. Micalizzi D, Maheswaran S, Haber D. A conduit to metastasis: circulating tumor cell biology. Genes & development. 2017;31(18):1827-40.
24. Agnoletto C, Corrà F, Minotti L, Baldassari F, Crudele F, Cook W, et al. Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers. 2019;11(4).
Table1. Baseline of the demographic and related clinical characteristics for patients diagnosed with colorectal cancer
|
Characteristics |
No. of colorectal cancer patients SEER (2010–2012) |
|
No. of colorectal cancer patients Dalian (2011–2015) |
|
||
|
With TDs （N=7096, 12.07%） |
Without TDs （N=51679, 87.92%） |
p value |
With TDs （N=207,27.90%） |
Without TDs （N=535,72.10%） |
p value |
|
|
Age, in years |
|
|
<0.001 |
|
|
0.826 |
|
<65 |
3263（13.80） |
20379（86.20） |
|
115（27.58） |
302（72.42） |
|
|
≥65 |
3833（10.91） |
31300（89.09） |
|
92（28.31） |
233（71.69） |
|
|
Sex |
|
|
0.217 |
|
|
0.011 |
|
Male |
3450（11.58） |
25530（88.42） |
|
137（31.42） |
299（68.58） |
|
|
Female |
3046（10.51） |
26149（89.49） |
|
70（22.89） |
236（77.11） |
|
|
Race |
|
|
0.230 |
|
|
|
|
White |
5687（12.05） |
41510（87.95） |
|
— |
— |
|
|
Black |
810（12.29） |
5780（87.71） |
|
— |
— |
|
|
Other |
559（12.00） |
4389（88.00） |
|
— |
— |
|
|
AJCC |
|
|
<0.001 |
|
|
<0.001 |
|
I |
66（0.47） |
13816（99.53） |
|
3（3.33） |
87（96.67） |
|
|
II |
582（3.02） |
18705（96.98） |
|
58（16.76） |
288（83.24） |
|
|
III |
3855（20.63） |
14830（79.37） |
|
109（44.49） |
136（55.51） |
|
|
IV |
2573（37.28） |
4328（62.72） |
|
37（60.66） |
24（39.34） |
|
|
T stage |
|
|
<0.001 |
|
|
<0.001 |
|
T1 |
104（1.40） |
7318（99.60） |
|
0（0） |
19（100） |
|
|
T2 |
258（2.73） |
9198（97.27） |
|
8（9.30） |
78（91.70） |
|
|
T3 |
4087（12.55） |
28487（87.45） |
|
6（10.71） |
50（89.29） |
|
|
T4 |
2647（28.39） |
6676（71.61） |
|
193（30.22） |
388（69.78） |
|
|
N stage |
|
|
<0.001 |
|
|
<0.001 |
|
N0 |
823（2.39） |
33611（97.61） |
|
70（15.35） |
386（84.65） |
|
|
N1 |
3095（20.92） |
11695（79.08） |
|
94（42.53） |
127（57.47） |
|
|
N2 |
3178（33.27） |
6373（66.73） |
|
43（66.15） |
22（33.85） |
|
|
M stage |
|
|
<0.001 |
|
|
<0.001 |
|
M0 |
4523（8.72） |
47351（91.28） |
|
151（22.27） |
527（77.73） |
|
|
M1 |
2573（37.28） |
4328（62.72） |
|
56（87.50） |
8（13.50） |
|
|
Primary site |
|
|
<0.001 |
|
|
0.199 |
|
Colon |
5509（11.84） |
40929（88.16） |
|
99（25.85） |
284（74.15） |
|
|
Rectum |
1587（12.97） |
10750（87.03） |
|
108（30.08） |
251（69.92） |
|
|
Grade |
|
|
<0.001 |
|
|
|
|
I |
274（5.99） |
4300（94.01） |
|
— |
— |
|
|
II |
4396（10.33） |
38149（89.67） |
|
— |
— |
|
|
III |
1909（19.90） |
7683（80.10） |
|
— |
— |
|
|
IV |
517（25.05） |
1547（84.95） |
|
— |
— |
|
|
Perineural invasion |
|
|
<0.001 |
|
|
|
|
None |
4761（9.11） |
47473（90.89） |
|
— |
— |
|
|
Yes |
2335（35.70） |
4206（64.30） |
|
— |
— |
|
|
Vascular tumor thrombus |
|
|
|
|
|
<0.001 |
|
None |
— |
— |
|
139（22.53） |
478（77.47） |
|
|
Yes |
— |
— |
|
68（54.40） |
57（45.60） |
|
|
Liver Met |
|
|
<0.001 |
|
|
<0.001 |
|
None |
5409（10.04） |
48492（89.96） |
|
153（23.29） |
504（76.71） |
|
|
Yes |
1687（34.61） |
3187（65.39） |
|
54（63.53） |
31（36.47） |
|
|
Lung Met |
|
|
<0.001 |
|
|
|
|
None |
6736（11.66） |
51015（88.34） |
|
— |
— |
|
|
Yes |
360（35.16） |
664（64.84） |
|
— |
— |
|
|
Bone Met |
|
|
<0.001 |
|
|
|
|
None |
7032（12.00） |
51584（88.00） |
|
— |
— |
|
|
Yes |
64（40.25） |
95（59.75） |
|
— |
— |
|
|
Brain Met |
|
|
0.002 |
|
|
|
|
None |
7082（12.06） |
51639（87.94） |
|
— |
— |
|
|
Yes |
14（25.93） |
40（74.07） |
|
— |
— |
|
Table2. Univariate and multivariate analyses of overall survival for the SEER cohort.
|
Variable |
Univariate Cox analysis |
Multivariate Cox analysis |
||
|
HR（95% CI） |
p value |
HR（95% CI） |
p value |
|
|
Age |
|
|
|
|
|
＜65 |
1 [Reference] |
|
1 [Reference] |
|
|
≥65 |
1.936 (1.879-1.995) |
＜0.001 |
2.362 (2.291-2.436) |
＜0.001 |
|
Sex |
|
|
|
|
|
Male |
1 [Reference] |
|
1 [Reference] |
|
|
Female |
1.052 (1.024-1.081) |
＜0.001 |
1.104 (1.075-1.135) |
＜0.001 |
|
Race |
|
|
|
|
|
Other |
1 [Reference] |
|
1 [Reference] |
|
|
White |
1.260 (1.194-1.329) |
＜0.001 |
1.245 (1.180-1.314) |
＜0.001 |
|
Black |
1.440 (1.350-1.535) |
＜0.001 |
1.497 (1.404-1.596) |
＜0.001 |
|
AJCC |
|
|
|
|
|
I |
1 [Reference] |
|
1 [Reference] |
|
|
II |
1.642 (1.568-1.720) |
＜0.001 |
0.962 (0.881-1.051) |
0.393 |
|
III |
2.333 (2.231-2.439) |
＜0.001 |
1.277 (1.147-1.423) |
＜0.001 |
|
IV |
7.674 (7.325-8.041) |
＜0.001 |
2.836 (2.532-3.176) |
＜0.001 |
|
T stage |
|
|
|
|
|
T1 |
1 [Reference] |
|
1 [Reference] |
|
|
T2 |
1.369 (1.278-1.467) |
＜0.001 |
1.220 (1.138-1.309) |
＜0.001 |
|
T3 |
2.416 (2.281-2.559) |
＜0.001 |
1.696 (1.548-1.859) |
＜0.001 |
|
T4 |
5.258 (4.948-5.586) |
＜0.001 |
2.647 (2.408-2.909) |
＜0.001 |
|
N stage |
|
|
|
＜0.001 |
|
N0 |
1 [Reference] |
|
1 [Reference] |
|
|
N1 |
1.663 (1.609-1.718) |
＜0.001 |
0.956 (0.885-1.032) |
0.248 |
|
N2 |
3.221 (3.117-3.328) |
＜0.001 |
1.365 (1.266-1.472) |
＜0.001 |
|
Primary site |
|
|
|
|
|
Rectum |
1 [Reference] |
|
1 [Reference] |
|
|
Colon |
1.326 (1.280-1.373) |
＜0.001 |
1.064 (1.026-1.103) |
0.001 |
|
Grade |
|
|
|
＜0.001 |
|
I |
1 [Reference] |
|
1 [Reference] |
|
|
II |
1.289 (1.215-1.366) |
＜0.001 |
1.023 (0.965-1.086) |
0.445 |
|
III |
2.225 (2.089-2.369) |
＜0.001 |
1.284 (1.204-1.370) |
＜0.001 |
|
IV |
2.554 (2.353-2.773) |
＜0.001 |
1.402 (1.289-1.524) |
＜0.001 |
|
TDs |
|
|
|
|
|
Negative |
1 [Reference] |
|
1 [Reference] |
|
|
Positive |
2.611 (2.526-2.699) |
＜0.001 |
1.346 (1.296-1.398) |
＜0.001 |
|
Perineural invasion |
|
|
|
|
|
Negative |
1 [Reference] |
|
1 [Reference] |
|
|
Positive |
2.143 (2.068-2.220) |
＜0.001 |
1.171 (1.127-1.216) |
＜0.001 |
|
Liver metastasis |
|
|
|
|
|
Negative |
1 [Reference] |
|
1 [Reference] |
|
|
Positive |
4.273 (4.126-4.425) |
＜0.001 |
1.318 (1.242-1.399) |
＜0.001 |
|
Lung metastasis |
|
|
|
|
|
Negative |
1 [Reference] |
|
1 [Reference] |
|
|
Positive |
4.232 (3.955-4.529) |
＜0.001 |
1.226 (1.139-1.319) |
＜0.001 |
|
Bone metastasis |
|
|
|
|
|
Negative |
1 [Reference] |
|
1 [Reference] |
|
|
Positive |
5.223 (4.422-6.168) |
＜0.001 |
1.368 (1.154-1.622) |
＜0.001 |
|
Brain metastasis |
|
|
|
|
|
Negative |
1 [Reference] |
|
1 [Reference] |
|
|
Positive |
6.603 (4.974-8.767) |
＜0.001 |
1.935 (1.452-2.579) |
＜0.001 |
Table 3. Univariate and multivariate logistic analyses of different metastatic patterns for the SEER and Dalian cohort.
|
Distant metastasis patterns |
Isolated organ metastasis OR (95% CI ) |
Multiple organ metastases OR (95% CI ) |
Isolated liver metastasis OR (95% CI ) |
Isolated lung metastasis OR (95% CI ) |
Liver metastasis OR (95% CI ) |
||
|
Univariate analysis TDs (+) vs TDs (-) |
4.375 (4.091-4.680) |
4.778 (4.109-5.556) |
4.395 (4.099-4.713) |
3.028 (2.414-3.797) |
5.738 (3.560-9.248) |
||
|
Multivariate analysis TDs (+) vs TDs (-) |
1.633 (1.514-1.761) |
1.667 (1.414-1.966) |
1.633 (1.510-1.766) |
1.402 (1.093-1.799) |
4.662 (2.743-7.923) |
||
Table 4. Survival Analysis according to clinical stage.
|
Clinical stage |
Mean survival (months) |
95% Confidence interval |
|
Stage IIIa |
60.259 |
59.393 - 61.124 |
|
Stage IIIb |
52.739 |
52.286 - 53.191 |
|
Stage IIIc |
41.481 |
40.584 - 42.378 |
|
T4aN2bM0 TDs (+) |
28.796 |
25.541 - 32.052 |
|
T4bN2M0 TDs (+) |
24.789 |
26.132 - 27.261 |
|
Stage IV |
29.355 |
28.616 - 30.094 |